+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Trastuzumab in metastatic breast cancer after complete remission: How long is enough?

Trastuzumab in metastatic breast cancer after complete remission: How long is enough?

Medical Oncology 32(8): 211

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 059163294

Download citation: RISBibTeXText

PMID: 26123599

DOI: 10.1007/s12032-015-0648-1

Related references

Long-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone. Breast Care 7(1): 45-47, 2012

Trastuzumab in metastatic breast cancer after complete remission: an expensive commitment for an entire life?. Current Oncology 24(1): E76-E77, 2017

Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report. Journal of Medical Case Reports 4: 401, 2010

Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?. Breast Cancer Research and Treatment 167(3): 815, 2017

Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature. Targeted Oncology 10(2): 297-301, 2016

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry. Bmc Cancer 14: 806, 2015

A retrospective series of long-term survivors of metastatic breast cancer in complete remission. Oncology 68(1): 48-51, 2005

How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?. Future Oncology 11(20): 2799-2801, 2016

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. Journal of Clinical Oncology 14(8): 2197-2205, 1996

Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report. Oncology Letters 14(2): 1725-1730, 2017

Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer. Collegium Antropologicum 36(1): 325-329, 2012

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Reports in Oncology 5(3): 687-692, 2013

Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. Tumori 99(3): E131-E133, 2013

Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission. Current Oncology 23(2): 91-95, 2016

Long term disease-free survival after stopping trastuzumab in trastuzumab-sensitive metastatic breast cancer patients treated with local-regional therapy. Journal of Clinical Oncology 26(15_suppl): 11542-11542, 2016